live sessions
PDT:
Pacific Daylight Time
PDT:
Pacific Daylight Time
Themed Discussion Sessions
Live Now:
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
Upcoming:
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Hide and Seek: HIV in Tissues
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
"Growing Up" With HIV Exposure
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
Previous:
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Hide and Seek: HIV in Tissues
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
"Growing Up" With HIV Exposure
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
